CO-DIAGNOSTICS INC. overview

LOS ANGELES, CA / ACCESSWIRE / August 26, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022, inclusive...

LOS ANGELES, CA / ACCESSWIRE / August 22, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022,...

LOS ANGELES, CA / ACCESSWIRE / August 19, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022, inclusive...

LOS ANGELES, CA / ACCESSWIRE / August 19, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022,...

LOS ANGELES, CA / ACCESSWIRE / August 17, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022, inclusive...

LOS ANGELES, CA / ACCESSWIRE / August 17, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ:CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 12, 2022 and August 11, 2022,...

Salt Lake City, Jan. 01, 2020 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming India Diagnostic Expo with its Indian joint venture, CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), on January 4-6 in Hyderabad, India, to formally launch their recently-approved in vitro diagnostics...

Salt Lake City, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Salt Lake City, Utah – October 29, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in a recent visit to Ghana the Company collaborated with Dare Labs to set up the largest private molecular diagnostics laboratory in Kumasi, the second largest city in Ghana, marking the Company’s expansion...